How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | INSMINSMED Inc | RVMDRevolution Medicines, Inc. | BIIBBIOGEN INC. | ALNYALNYLAM PHARMACEUTICALS, INC. | Median of the restexcluding INSM |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $94.04▼ 1.63 (1.70%) | $194.28▼ 2.27 (1.15%) | $240.98▼ 2.12 (0.87%) | $225.10▼ 5.61 (2.43%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 5.0/10 | 2.0/10 | 9.0/10 | 7.3/10 | 7.3/10 |
| Market value | $20.15B | $38.27B | $35.38B | $29.80B | |
| Revenue | $606.4M | $0.00 | $9.89B | $3.71B | |
| Profit | -$1.28B | -$1.13B | $1.29B | $313.7M | |
| Revenue growthChange in sales versus the prior year. | 66.7% | — | 2.2% | 65.2% | 33.7% |
| Gross marginShare of sales left after the direct cost of producing them. | 79.7% | — | 75.7% | 81.8% | 78.7% |
| Operating marginShare of sales left after running the business, before interest and tax. | -205.6% | — | — | 13.5% | 13.5% |
| Profit marginProfit kept from each dollar of sales. | -210.5% | — | 13.1% | 8.4% | 10.8% |
| Free cash flow marginCash left after capital spending, as a share of sales. | -159.6% | — | 20.7% | 12.5% | 16.6% |
| Return on equityProfit against the owners' stake in the company. | -172.8% | -69.3% | 7.1% | 39.8% | 7.1% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | -128.0% | -74.9% | — | — | -74.9% |
| P/E ratioPrice paid per dollar of annual profit. | — | — | 27.36x | 94.97x | 61.17x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | — | — | — |
| Price to book | 27.27x | 23.46x | 1.94x | 37.76x | 23.46x |
| Debt to equityTotal liabilities compared with owners' stake. | 2.06x | 0.44x | 0.61x | 5.29x | 0.61x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 4/9 | 1/7 | 6/9 | 5/8 | 5.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | safe | safe | safe |
How INSM compares with the others
- INSM's operating margin of -205.6% is lower than the other company selected (13.5%).
- Its revenue grew faster than the median of the other companies selected: 66.7% against 33.7%.
- It has no P/E to set against theirs, because it did not make a profit.
- Its liabilities are higher relative to equity than the median of the other companies selected: 2.1x against 0.6x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.